Drugs by condition
Drugs approved for mash (fatty liver disease)
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
2
Still marketed, NDA or BLA
Drug classes
2
Novel drugs
2
New molecular entities and new biologics
In development
29
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for mash (fatty liver disease).
All approved drugs for mash (fatty liver disease), by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Drugs in development for mash (fatty liver disease)
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- IBI362Phase 38 trials
Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- Saroglitazar MagnesiumPhase 35 trials
Zydus Therapeutics Inc. · Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Fibrosis
- ALN-CIDEBPhase 34 trials
Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD
- HTD1801Berberine UrsodeoxycholatePhase 34 trials
Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- PemvidutidePhase 34 trials
Altimmune, Inc. · Alcohol-associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD)
- EfruxiferminPhase 33 trials
Akero Therapeutics, Inc · NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH/MASH
- pegargiminaseADI-PEG 20Phase 33 trials
Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
- PegozaferminBIO89-100Phase 33 trials
Roche (Genentech) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia
- HSK31679Phase 32 trials
Haisco Pharmaceutical Group Co., Ltd. · MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis), Non-Alcoholic Steatohepatitis (NASH)
- IVA337LanifibranorPhase 31 trial
Inventiva Pharma · NASH - Nonalcoholic Steatohepatitis
- HRS-4729Phase 23 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Metabolic Dysfunction-Associated Steatohepatitis (MASH), Type 2 Diabetes, Overweight or Obesity
- ARO-INHBEPhase 22 trials
Arrowhead Pharmaceuticals · Metabolic Dysfunction-Associated Steatohepatitis, Obesity
- ECC4703Phase 22 trials
Eccogene · Adult Obesity, Weight Management, Metabolic Dysfunction-associated Steatohepatitis
- EfinopegdutideMK-6024, HM12525APhase 22 trials
Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
- HU6Phase 22 trials
Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- NNC0194-0499Phase 22 trials
Novo Nordisk · Alcohol-related Liver Disease, Non-alcoholic Steatohepatitis
- AZD2693Phase 21 trial
AstraZeneca · Nonalcoholic Steatohepatitis
More on mash (fatty liver disease): recruiting trials · published research
Related in gastroenterology and liver: Primary biliary cholangitis · Acid reflux (GERD) · Irritable bowel syndrome · Chronic constipation · Nausea and vomiting · Eosinophilic esophagitis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.